GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (LTS:0HOJ) » Definitions » Valuation Rank

Blueprint Medicines (LTS:0HOJ) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is Blueprint Medicines Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Blueprint Medicines Valuation Rank Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines (LTS:0HOJ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (LTS:0HOJ) » Definitions » Valuation Rank
Comparable Companies
KRYS INSM FOLD NUVL IMGN CRSP CYTK ACAD TRML AXSM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
BPMC:USA 2L9:Germany
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Website
https://www.blueprintmedicines.com
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.